Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond T Bartus

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Experimental Neurology|January 5, 2002
The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct?Dwaine F Emerich, Reginald L Dean, Raymond T Bartus
Brain Research|November 26, 2002
Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicityCesario V Borlongan, Dwaine F Emerich, Barry J Hoffer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 16, 2016
Trophic factors for Parkinson's disease: To live or let dieC Warren Olanow, Raymond T Bartus, Laura A Volpicelli-Daley, et al.
Brain : a Journal of Neurology|March 24, 2020
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's diseaseYaping Chu, Raymond T Bartus, Fredric P Manfredsson, et al.
Neurobiology of Disease|October 14, 2015
β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS)Raymond T Bartus, Alexandre Bétourné, Anthony Basile, et al.
Drug Delivery and Translational Research|March 20, 2015
Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseasesChristopher D Herzog, Kathie M Bishop, Lamar Brown, et al.
Experimental Neurology|April 29, 2008
Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neuronsKathie M Bishop, Eva K Hofer, Arpesh Mehta, et al.
Neurobiology of Aging|August 29, 2012
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's diseaseRaymond T Bartus, Tiffany L Baumann, Lamar Brown, et al.
Parkinsonism & Related Disorders|November 19, 2008
Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference pointRaymond T Bartus, Christopher D Herzog, Kathie Bishop, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 22, 2003
Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in ratsRaymond T Bartus, Dwaine F Emerich, Joyce Hotz, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Experimental Neurology|January 5, 2002
The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct?Dwaine F Emerich, Reginald L Dean, Raymond T Bartus
Brain Research|November 26, 2002
Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicityCesario V Borlongan, Dwaine F Emerich, Barry J Hoffer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 16, 2016
Trophic factors for Parkinson's disease: To live or let dieC Warren Olanow, Raymond T Bartus, Laura A Volpicelli-Daley, et al.
Brain : a Journal of Neurology|March 24, 2020
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's diseaseYaping Chu, Raymond T Bartus, Fredric P Manfredsson, et al.
Neurobiology of Disease|October 14, 2015
β2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS)Raymond T Bartus, Alexandre Bétourné, Anthony Basile, et al.
Drug Delivery and Translational Research|March 20, 2015
Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseasesChristopher D Herzog, Kathie M Bishop, Lamar Brown, et al.
Experimental Neurology|April 29, 2008
Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neuronsKathie M Bishop, Eva K Hofer, Arpesh Mehta, et al.
Neurobiology of Aging|August 29, 2012
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAV-neurturin (CERE-120) in Parkinson's diseaseRaymond T Bartus, Tiffany L Baumann, Lamar Brown, et al.
Parkinsonism & Related Disorders|November 19, 2008
Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference pointRaymond T Bartus, Christopher D Herzog, Kathie Bishop, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 22, 2003
Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in ratsRaymond T Bartus, Dwaine F Emerich, Joyce Hotz, et al.
Pageof 5